Updates

Politico: ICER Revises Migraine Report, But Advocacy Groups Still Not Satisfied

02.28.20

The Institute for Clinical and Economic Review revised its previous assessment of two new migraine drugs, determining that they meet its long-term cost-effectiveness thresholds — after previously ruling the cost of the medicines was too high. The final evidence report concluded that Allergan’s Ubrelvy, which costs $4,896 a year, and Biohaven’s rimegepant meet the cost-effectiveness threshold.